Wanbury's Patalganga site completes MFDS inspection successfully

Wanbury Limited, Patalganga site has completed MFDS (Ministry of Food and Drug Safety - Korea FDA) Regulatory Inspection successfully. Two inspectors inspected facility for three days i.e. from 7th April 2026 to 9th April, 2026. Inspection completed with no observation (Zero Observation) confirming cGMP compliance per international rules.

MFDS is part of PIC (Pharmaceutical inspection co-operation scheme). Company is strengthening infrastructure by adding new state of the art manufacturing block at Andhra Pradesh site for new APIs which under validation and commercialisation.

Both the API manufacturing sites are USFDA approved i.e. Patalganga and Tanuku of WL are continued to be compliant as per cGMP Rules and Regulations with Zero Observation.

Patalganga plant received zero observation from USFDA earlier. Thereafter, Tanuku plant received Zero Observation from Anvisa (Brazil FDA). Now again, Patalganga plant got Korea FDA Approval with Zero Observation.

Shares of Wanbury Limited was last trading in BSE at Rs. 258.00 as compared to the previous close of Rs. 260.30. The total number of shares traded during the day was 2402 in over 43 trades.

The stock hit an intraday high of Rs. 269.90 and intraday low of 256.20. The net turnover during the day was Rs. 632989.00.

Source : Equity Bulls

Keywords

Wanbury INE107F01022 Pharmaceuticals Patalganga MFDS Inspection